Overall survival for patients with many types of tumours has improved thanks to developments in cutting-edge technology, trendy diagnostic and prognostic molecular markers, and cutting-edge surgical procedures. However, there is a gap between esophageal cancer and the rapid advancements in cancer treatment found in other cancers. The 5-year survival rate for patients with esophageal cancer is just 19.9%, according to statistics from the Surveillance, Epidemiology, and End Results Program (SEER) [1]. Poor prognosis is most likely attributable to an overabundance of patients with advanced disease at the time of diagnosis, as well as the disappointing results of present treatments. The epidemiology and recently revised staging of esophageal and esophagogastric junction tumours will be discussed in this article. Endoscopic resection, surgery, radiation therapy, and systemic therapy will be discussed individually and as components of multimodality treatment. We'll go over how targeted therapy and immunotherapy have changed the treatment environment. Clinical research is shifting away from classic empiric chemotherapy and toward more customised treatments based on molecular oncology and immunotherapy. Further research into prognostic values may aid in determining the best treatment and management strategy for patients with esophageal cancer, with the goal of improving survival. Lessons obtained in epidemiology, molecular genetics, pharmacogenomics, and precision medicine are used to inform clinical trials examining prevention, early diagnosis, and therapy of early and advanced disease.
Author(s) DetailsNicole B. Balmaceda
University of Kansas School of Medicine, University of Kansas, 3901 Rainbow Blvd, Kansas City, Kansas 66160, USA.
Joaquina C. Baranda
Department of Hematology and Medical Oncology, University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Westwood, KS 66205, USA.
Peter DiPasco
Department of Surgery, University of Kansas, 3901 Rainbow Blvd, Kansas City, Kansas 66160, USA.
Weijing Sun
Department of Hematology and Medical Oncology, University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Westwood, KS 66205, USA.
John Ashcraft
Department of Hematology and Medical Oncology, University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Westwood, KS 66205, USA.
Joseph Valentino
Department of Hematology and Medical Oncology, University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Westwood, KS 66205, USA.
Mazin Al-Kasspooles
Department of Hematology and Medical Oncology, University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Westwood, KS 66205, USA.
View Book :- https://stm.bookpi.org/HMMR-V10/article/view/1127
No comments:
Post a Comment